Filtered By:
Specialty: Urology & Nephrology
Cancer: Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2953 results found since Jan 2013.
Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods —what’s around the corner?
ConclusionCurrent diagnostic methods for UTUC have shortcomings, especially concerning prognostication, which is important for personalized treatment decisions. There are several upcoming methods that may be of interest for UTUC. Most have been studied for urothelial carcinoma of the bladder, and it is important to keep in mind that UTUC is a different entity and not all methods are adaptable or applicable to UTUC.
Source: World Journal of Urology - September 19, 2023 Category: Urology & Nephrology Source Type: research
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab
CONCLUSIONS: Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients.PMID:37722984 | DOI:10.1016/j.urolonc.2023.08.009
Source: Urologic Oncology - September 18, 2023 Category: Urology & Nephrology Authors: Neil J Shah Sneha D Sura Reshma Shinde Junxin Shi Puneet Singhal Rodolfo F Perini Robert J Motzer Source Type: research
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma
CONCLUSIONS: Black patients with RCC demonstrate worse survival outcomes compared to White patients across all stages. Socioeconomic disparities between races play a significant role in influencing survival in RCC.PMID:37709565 | DOI:10.1016/j.urolonc.2023.08.016
Source: Urologic Oncology - September 14, 2023 Category: Urology & Nephrology Authors: Ridwan Alam Michael E Rezaee Maximilian Pallauf Roy Elias Anirudh Yerrapragada Dmitry Enikeev Dong Fang Shahrokh F Shariat Solomon L Woldu Yasser M A Ged Nirmish Singla Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management
CONCLUSIONS: This is to our knowledge the first study that compared the PROs with clinician reported functional outcomes and the impact of discrepancies on the management of side effects of RARP in prostate cancer. Observed discrepancies between the PROs and CROs did not affect offered management and counseling of UI and ED.PMID:37690935 | DOI:10.1016/j.urolonc.2023.08.001
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: C N Tillier A H Boekhout H Veerman B M Wollersheim Pam Groen H G van der Poel L V van de Poll-Franse Source Type: research
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment
CONCLUSIONS: The success of BCG treatment in NMIBC was not related to PD-L1, PD-L2, and STAT3 expression status, but PD-L1 expression was correlated with both PD-L2 and STAT3 as well as TILs rate, but this correlation was lost after BCG treatment.PMID:37690934 | DOI:10.1016/j.urolonc.2023.08.012
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Aziz Hakk ı Civriz Kerem Teke Enes Malik Akdas Ozdal Dillioglugil Cigdem Vural Busra Yaprak Bayrak Source Type: research
Preoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis
CONCLUSION: CIN level of preoperative urine exfoliated cells had robust prognostic value for bladder cancer patients underwent TURBT. The prognostic model by combining CIN and EORTC may help in stratifying patients to optimize follow-up regimen.PMID:37652824 | DOI:10.1016/j.urolonc.2023.06.012
Source: Urologic Oncology - August 31, 2023 Category: Urology & Nephrology Authors: Yidie Ying Zhensheng Zhang Naidong Xing Ziliang Qian Baiyun Wang Shuxiong Zeng Chuanliang Xu Source Type: research
